F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
0 hedge funds and large institutions have $0 invested in F-star Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 59 closing their positions.
100% less funds holding
Funds holding: 59 → 0 (-59)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $57.8M → $0 (-$57.8M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 59
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$6.32M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$4.75M |
| 3 |
TC
Trium Capital
London,
United Kingdom
|
-$4.3M |
| 4 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$3.79M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$3.65M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CC
51
Cannell Capital
Alta,
Wyoming
| – | -$46.4K | -7,345 | Closed |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| – | -$24K | -3,724 | Closed |
|
53
Osaic Holdings
Scottsdale,
Arizona
| – | -$15K | -2,424 | Closed |
|
|
FIA
54
FNY Investment Advisers
New York
| – | -$6K | -1,000 | Closed |
|
55
Wells Fargo
San Francisco,
California
| – | -$1.71K | -270 | Closed |
|
56
Group One Trading
Chicago,
Illinois
| – | -$1.11K | -175 | Closed |
|
57
Morgan Stanley
New York
| – | -$272 | -43 | Closed |
|
FSTX Hedge Fund Activity: Q1 2023 in Review
0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q1 2023, worth a combined $0 — down 100% from $57.8M a quarter earlier.
Sellers outnumbered buyers: 59 funds closed out of FSTX and 0 opened new positions — a net loss of 59 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Armistice Capital, exiting entirely with an estimated $6.32M sold.
- 0 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q1 2023, down from 59 in Q4 2022.
- Funds reported $0 of F-star Therapeutics, Inc. Common Stock stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q1 2023 and 59 closed out, a net change of -59 holders.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q1 2023 was Armistice Capital, an estimated $6.32M sold.
Based on aggregated 13F filings for Q1 2023.